Overview

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

Status:
Completed

Trial end date:
2019-09-09

Target enrollment:

Participant gender:

Summary

This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe alcoholic hepatitis (AH).

Phase:

Phase 2

Details

Lead Sponsor:

Durect

Collaborators:

CTI Clinical Trial & Consulting Services
CTI Clinical Trial and Consulting Services